Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. - Wikidata - wikimedia - TriplyDB

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

http://www.wikidata.org/entity/Q33794311

about

Management of Chronic Lymphocytic Leukemia in the Elderly Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.Initial treatment of CLL: integrating biology and functional status.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.New oral small molecules in the treatment of chronic lymphocytic leukemia.What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.How I manage patients with hairy cell leukaemia.Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in no Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.Updates from the 2017 American Society of Hematology annual meeting: practice-changing studies in untreated chronic lymphocytic leukemia.

P2860

Q26775983-16D80D59-8020-4B71-BE6A-E4D5DFF95FA0 Q33421376-BAFD476E-4C3D-4D79-A2ED-E2AD832CBE3F Q33424056-CD3E64E4-4089-457F-92D8-E4B793A9160B Q33424781-B091F7F9-7DBA-43BF-9CF0-F20BCACF74F0 Q34463414-E99DDDAB-F7B3-450B-A348-777C9B7500C1 Q34625543-AC84C100-E45A-4321-A49C-ADBDAB1E2CDE Q35571040-D624E614-7133-4D27-8210-8259087704D2 Q35953518-76C0D4C4-8705-46D4-BD51-0B063DA1C816 Q36219647-1546D9ED-15B3-4DFD-97CE-33F95A2D30D1 Q36550468-0B4FCA7B-0B8E-46D3-ABBE-78294AD765E3 Q36743899-B0A59A55-7EBB-4E21-8129-C542B2DC265D Q36788133-8C06C487-3386-449E-B6FE-C2D1A0250403 Q36799192-54E00241-C58A-4228-AD81-1BC6FF7622BC Q37638782-C57F58DD-7F47-415C-8EE3-011BB1FD37A1 Q38359004-F9F48402-557A-4391-90C2-2BFD6067E751 Q38586543-705EBF3C-BCFF-4F1B-AC18-808EBB74562D Q38672646-3B3DB3D1-5EB4-4F80-A162-F194CBF77CD9 Q38818283-D0B18453-5F6E-4389-8024-EA7A5D8DC07E Q38851368-FF1F7282-498C-40E0-B18A-38508D8B9569 Q38997367-91FC45DC-7FB9-4449-AC6B-12077C0A618B Q39113513-7E861EB8-6A24-45AE-BF6C-1AE9DF8164F2 Q39145934-27E0EF83-99B2-4C02-88F8-17E1E8EF8DD1 Q39154057-564B0AEA-C3BF-4DAB-9F21-9056184EE59A Q39324849-12D86E17-8882-4020-85E5-A8A2DA062626 Q40403542-724B6C83-B41A-440A-8A83-F41977BCDFCD Q40954148-BA8609AC-D589-489D-9691-374D6229249E Q41125227-74A9588C-CA88-461F-BB90-06AB9AA617E0 Q49818588-1C98B627-119C-4ADA-B3AB-5C50F09F89B0 Q50025029-96015810-227C-4144-97F2-6C869AEE2CA9 Q51007218-473A5E1A-A1D0-4874-8C5D-3F6DEAC9B1C6 Q51014811-5D12A282-9634-4E6F-BCB9-5B645526A402 Q52770382-17CAA082-5BD5-4CE9-A840-4D5936F3F146 Q52812536-C3DD876E-D0D8-41D1-8D14-C4521F4A7CDD Q53963822-C17CD2CC-988B-4A76-9934-364B8D56DA91 Q54116803-92C208DA-4FAE-401C-AE18-738FD154CC9A Q55069042-17F1E51F-FE3A-453C-AFB1-5BBEB29D0FF4

P2860

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

http://www.wikidata.org/entity/Q33794311

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Eradication of bone marrow min ...... atment discontinuation in CLL.

@ast

Eradication of bone marrow min ...... atment discontinuation in CLL.

@en

type

label

Eradication of bone marrow min ...... atment discontinuation in CLL.

@ast

Eradication of bone marrow min ...... atment discontinuation in CLL.

@en

prefLabel

Eradication of bone marrow min ...... atment discontinuation in CLL.

@ast

Eradication of bone marrow min ...... atment discontinuation in CLL.

@en

P1433

Q33794311-DB6C3147-2BFD-4699-96AB-8FA152544724

P1476

Q33794311-B0FCCC33-C063-4D7C-A266-F2397A46B302

P2093

Q33794311-2B039265-B6BC-44AE-AD8F-9706489275F5

Q33794311-30705DD0-5A03-4432-8148-A7E3434BFCF6

Q33794311-3E24D060-5DB9-4FEF-AF3F-3731A65AFD31

Q33794311-502D4DF2-F7E8-42A0-9D3C-0206BDC25FE0

Q33794311-59013774-79E2-4360-AFB4-3A47BE9E4DF4

Q33794311-A916155B-EA8C-45FA-94EF-BD313E460FF8

Q33794311-C0BB4332-E7EB-460F-A822-FC1C6B708264

Q33794311-F2F038CB-0922-4DB4-BA0A-0B07B90C41B7

P2860

Q33794311-0CBC42BE-AC97-4E66-9409-D92831A23444

Q33794311-0F956CF9-8A1D-4438-9611-23275032C434

Q33794311-0FD2C011-91C3-4E9E-9251-975102FCAEFD

Q33794311-10F21371-6BAE-4F44-93D0-25469171647E

Q33794311-160DF31E-61F7-479F-8FC1-6C7FE8E0AD0C

Q33794311-27D75A41-9942-42DB-9E05-CB5BB123942F

Q33794311-2B48B93F-4A1C-48A9-A884-F7DDC0849605

Q33794311-42737C6B-E0A2-445C-A20F-E82ABDC2D88F

Q33794311-431732FD-9F3B-43F3-B952-88FF08D2ADC0

Q33794311-6F6030FC-5450-4A3D-BF4B-886A161527EC

P304

Q33794311-8D96DA21-EEE6-4156-A432-E0EC81F5AA69

P31

Q33794311-627601B0-6943-41DA-9D72-8E508AB7A841

P356

Q33794311-C5B806A2-FC5A-4320-A179-F6E8B53D8A62

P407

Q33794311-9CFFB8FF-DA67-4423-B065-305A4F9768D0

P433

Q33794311-DDFF3826-F6B5-46AF-89A7-51ECD825EF45

P478

Q33794311-05C0AC22-ED4F-465D-8EE2-BFC6BA709358

P50

Q33794311-65A19493-7A29-4B67-9EFD-356F0202D37A

Q33794311-8956BAEA-17A8-4AE3-B01E-168AC9D675F3

Q33794311-A403FF23-6BC9-4225-9A3F-8B5396CB4322

Q33794311-C3F8CDE1-A713-4593-A641-F918CAB200EB

P577

Q33794311-68F9E7A4-6D41-4FB8-9D6B-326F883DB9F8

P5875

Q33794311-DD75B26C-66AD-4B11-A222-C92BC19E2163

P698

Q33794311-F2CF9B03-21EB-4E1E-8BEF-9688149F7479

P921

Q33794311-0CCFA94D-152E-446B-8C26-06B8D68B1253

P932

Q33794311-2D652B06-1ADC-40F6-89F7-7FAA7DC2630B

P356

BLOOD-2013-11-538116

P1433

P1476

Eradication of bone marrow min ...... atment discontinuation in CLL.

@en

P2093

Francesco Paolo Tambaro

http://www.w3.org/2001/XMLSchema#string

Jan Burger

http://www.w3.org/2001/XMLSchema#string

Jeffrey Jorgensen

http://www.w3.org/2001/XMLSchema#string

Nitin Jain

http://www.w3.org/2001/XMLSchema#string

Paolo Strati

http://www.w3.org/2001/XMLSchema#string

Pramoda Challagundla

http://www.w3.org/2001/XMLSchema#string

Stefan H Faderl

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Is MRD eradication a desirable goal in CLL?

Assessment of minimal residual disease in acute myeloid leukemia.

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

P304

3727-3732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-538116

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2014-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261408577

http://www.w3.org/2001/XMLSchema#string

P698

24705492

http://www.w3.org/2001/XMLSchema#string

P921

eradication of infectious diseases

P932

4067501

http://www.w3.org/2001/XMLSchema#string